When I first covered Telix Pharmaceuticals (NASDAQ: TLX ) back in May, I expressed substantial confidence in the outlook for the investment thesis, based on the strong sales growth of their imaging diagnostics bridging the development I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burn ...